With the clinical development of XORLO TM1 having advanced sufficiently, including completion of a pivotal program, XORTX is initiating discussions for the XRx-026 program with the US Food and Drug ...

Insight into the immunopathogenesis of crystal-induced inflammation has opened the door to a new approach to therapy. Could interleukin-1 antagonists be the answer to managing acute gout?

This new study not only clarifies the causes of gout but also helps scientists explore more treatment options. Existing drugs ...

In addition to adherence challenges, discontinuation of prescription treatment due to adverse effects is also a challenge in the medical management of gout.

Gout tophi totally disappeared and renal function remained stable. The patient continues to receive rasburicase treatment. P Richette is a Rheumatologist and T Bardin is a Professor of ...

It has been awarded a fast-track review by the FDA, which Sobi said “underscores the urgent need for new treatment options for patients with chronic refractory gout.” If approved, it will ...

Although the incidence of gout could be similar in men and women >60 years of age, most research has focused on the epidemiology and treatment of this disease in men. Harrold and colleagues have ...

Doctor Edward Dwyer knows gout when he sees it. The throbbing agony drives many patients to seek medical help. Doctors generally prescribe one of three different treatments fo this type of searing ...